ProMIS Neurosciences, Inc. (PMN)
9.035
+0.94
(+11.68%)
USD |
NASDAQ |
Oct 21, 16:00
9.035
0.00 (0.00%)
After-Hours: 18:51
ProMIS Neurosciences Enterprise Value : 19.09M for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | 19.09M |
| October 19, 2026 | 20.34M |
| October 16, 2026 | 19.62M |
| October 15, 2026 | 24.56M |
| October 14, 2026 | 20.83M |
| October 13, 2026 | 24.20M |
| October 12, 2026 | 31.28M |
| October 09, 2026 | 32.72M |
| October 08, 2026 | 28.59M |
| October 07, 2026 | 28.32M |
| October 06, 2026 | 29.13M |
| October 05, 2026 | 30.56M |
| October 02, 2026 | 30.83M |
| October 01, 2026 | 30.65M |
| September 30, 2026 | 43.84M |
| September 29, 2026 | 41.91M |
| September 28, 2026 | 42.04M |
| September 25, 2026 | 47.60M |
| September 24, 2026 | 50.29M |
| September 23, 2026 | 62.58M |
| September 22, 2026 | 68.32M |
| September 21, 2026 | 68.77M |
| September 18, 2026 | 72.17M |
| September 17, 2026 | 67.24M |
| September 16, 2026 | 62.04M |
| Date | Value |
|---|---|
| September 15, 2026 | 62.13M |
| September 14, 2026 | 65.45M |
| September 11, 2026 | 68.14M |
| September 10, 2026 | 66.70M |
| September 09, 2026 | 75.36M |
| September 08, 2026 | 58.90M |
| September 04, 2026 | 59.53M |
| September 03, 2026 | 62.22M |
| September 02, 2026 | 71.86M |
| September 01, 2026 | 66.26M |
| August 31, 2026 | 63.74M |
| August 28, 2026 | 70.16M |
| August 27, 2026 | 72.00M |
| August 26, 2026 | 76.21M |
| August 25, 2026 | 84.28M |
| August 24, 2026 | 79.26M |
| August 21, 2026 | 76.66M |
| August 20, 2026 | 80.25M |
| August 19, 2026 | 78.00M |
| August 18, 2026 | 80.87M |
| August 17, 2026 | 78.00M |
| August 14, 2026 | 79.80M |
| August 13, 2026 | 79.17M |
| August 12, 2026 | 76.57M |
| August 11, 2026 | 80.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 25.25M |
| Arrowhead Pharmaceuticals, Inc. | 8.090B |
| Oncolytics Biotech, Inc. | 58.48M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 2.282B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.73M |
| Total Expenses (Quarterly) | 11.73M |
| EPS Diluted (Quarterly) | -1.283 |
| Earnings Yield | -148.7% |
| Normalized Earnings Yield | -148.70 |